EVT-103
| Clinical data | |
|---|---|
| Synonyms | ENS-103 |
| Routes of administration | By mouth |
| Drug class | NMDA receptor antagonist |
EVT-103, also known as ENS-103, is an experimental medication which originated from Roche and is under development by Evotec AG for the treatment of major depressive disorder.[1] It acts as an NMDA receptor subunit 2B (NR2B) antagonist.[1] As of November 2017, no recent reports of development for major depressive disorder have been identified.[1] The drug was developed as a follow-up compound to EVT-101.[2] The chemical structure of EVT-103 has not been released.[2]
See also
References
- 1 2 3 http://adisinsight.springer.com/drugs/800030864
- 1 2 Ruppa, Kamalesh B.; King, Dalton; Olson, Richard E. (2012). "NMDA Antagonists of GluN2B Subtype and Modulators of GluN2A, GluN2C, and GluN2D Subtypes—Recent Results and Developments". 47: 89–103. doi:10.1016/B978-0-12-396492-2.00007-2. ISSN 0065-7743.
External links
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.